Health Canada’s draft revised Natural Health Product (NHP) Quality Guide signals a shift toward lifecycle quality oversight for NHPs, with greater attention to specifications, stability, supplier controls, quality agreements and post-licensing documentation. Source Nutraceutical, Inc. (SNI) helps NHP brands understand what these proposed changes could mean in practice and how to prepare without overcorrecting before the final guide is published.
Health Canada’s Draft NHP Quality Guide
Health Canada has released a draft revised Quality of Natural Health Products Guide that could significantly change how NHP companies manage quality in Canada.
The current guide, published in 2015, is largely focused on establishing product specifications and supporting Natural Product Number (NPN) applications. The proposed 2026 guide takes a broader approach by treating quality as an ongoing responsibility that extends across the full product lifecycle.
For NHP brands, the draft guide reinforces that obtaining an NPN is not the end of the quality process. Companies are already expected to demonstrate that appropriate quality controls are in place; however, the proposed guide places greater emphasis on clearly showing Health Canada that proper documentation and controls support ongoing quality oversight. This focus is particularly important for Canadian sites involved in NHP handling, whether through domestic manufacturing and production or through the importation of foreign products.
The revised guide is currently a consultation draft and is not yet in effect. However, it provides an important indication of how Health Canada’s expectations for NHP quality may evolve.
- What Is Changing in Health Canada’s NHP Quality Framework?
- Product Licence Holders May Face Greater Ongoing Accountability
- Quality Agreements May Become More Important
- Quality Would Become a Shared Supply-Chain Responsibility
- Raw Material and Supplier Controls May Require Greater Attention
- Stability May Become a More Visible Ongoing Requirement
- Dosage Form-Specific Quality Expectations Are More Clearly Defined
- Could the Draft Guide Affect Inspections?
- How Should Brands Prepare for the Proposed Quality of Natural Health Products (NHPs) Guide?
- Which NHP Brands May Be Most Affected by the New Quality of Natural Health Products (NHPs) Guide?
- Frequently Asked Questions
- Final Remarks
What Is Changing in Health Canada’s NHP Quality Framework?
The proposed guide represents a shift from a primarily application-focused model to a broader lifecycle quality framework.
Under the current approach, much of the quality work is concentrated during product licensing, when companies establish finished product specifications (FPS) and provide the information needed to support an NPN application.
The draft guide places greater emphasis on ongoing quality management, including:
- Raw material sourcing and characterization
- Manufacturing and testing
- Product release
- Stability monitoring
- Supplier and contractor oversight
- Post-licensing changes
- Record maintenance
- Post-market quality issues
In practice, brands may need more formal systems to ensure that quality documentation remains current after a product reaches the market.
Product Licence Holders May Face Greater Ongoing Accountability
Product Licence holders are already responsible for the quality of their licensed products, including maintaining appropriate specifications and ensuring that products continue to meet quality requirements through the end of their shelf life.
The proposed guide does not fundamentally change this accountability. Instead, it provides more detailed direction on how Product Licence holders should maintain current specifications, support stability, assess supplier and manufacturing changes, address quality issues, and oversee outsourced activities.
For brands, particularly those that outsource manufacturing, testing, importation and distribution, the practical change may be greater scrutiny of how these existing responsibilities are documented and managed across the product lifecycle.
What Greater Product Licence Holder Accountability May Look Like in Practice?
A brand holds the NPN for a gummy supplement but relies on a contract manufacturer for production and testing.
Under the current, more application-focused approach, the brand may continue relying on the original specifications where the medicinal ingredients, claims and label remain unchanged.
Under the proposed lifecycle approach, the brand may need to document a formal change assessment. This could include reviewing the nature of the change, identifying which quality attributes may be affected, comparing the revised process or material against the approved specifications, and determining whether additional testing or stability data are needed.
For example, a change to the gummy base could affect water activity, microbial risk, ingredient distribution, texture or disintegration. A supplier change could require comparison of raw material specifications, source, manufacturing method and contaminant controls. A process change could require confirmation that the existing analytical methods and release limits remain suitable.
The outcome should be documented and may result in no further action, targeted verification testing, updated specifications, additional stability monitoring or a regulatory assessment to determine whether a licence amendment is required.
Quality Agreements May Become More Important
Written quality agreements are already used to assign responsibilities for outsourced activities. The proposed guide does not introduce the concept for the first time, but it places greater emphasis on how these agreements should be structured and maintained.
The draft provides more detailed direction on assigning responsibility for specification development, raw material and finished product testing, stability studies, deviation investigations, supplier and manufacturing changes, record retention, product release and escalation of quality issues.
For brands, this may result in greater scrutiny of whether commercial contracts clearly address regulatory and quality responsibilities. A standard manufacturing or supply agreement may not be sufficient where it does not define who owns the records, who investigates problems and who must inform the Product Licence holder when a quality issue arises.
What More Formal Quality Agreements Could Look Like?
A contract laboratory identifies that a test method may not be suitable for the finished product, but the manufacturer does not inform the Product Licence holder.
Under a less formal arrangement, the issue may remain between the laboratory and manufacturer, leaving the brand unaware that the method used to release the product may be unreliable.
Under the proposed approach, the quality agreement should specify who must be notified, how quickly the issue must be escalated, who leads the investigation, and whether affected batches must be reassessed.
The investigation may include reviewing the method’s suitability, identifying which lots were tested, determining whether previous results remain reliable, and deciding whether additional testing, revised specifications, or corrective actions are required. The agreement should also identify who documents and approves the outcome and whether supporting information must be provided to Health Canada.
Quality Would Become a Shared Supply-Chain Responsibility
Quality responsibilities already extend beyond the Product Licence holder and manufacturer. The proposed guide does not create an entirely new shared-responsibility model, but it describes more clearly how quality should be managed across the organizations involved in producing, testing, importing, storing and distributing an NHP.
These parties may include contract manufacturers, packagers, labellers, importers, distributors, warehouses, and testing laboratories.
For brands, this change may introduce greater scrutiny of whether each party is working from the same approved specifications, understands its assigned responsibilities, and communicates quality issues or changes to the appropriate organizations.
What Shared Supply-Chain Responsibility Could Look Like?
A foreign manufacturer, Canadian importer, and Product Licence holder each maintain a different version of the FPS.
Under a less coordinated approach, each party may apply its own testing limits or methods without confirming that the documents are aligned. This can create uncertainty about which specification governs product release and whether the released product meets the requirements established by the Product Licence holder.
Under the proposed lifecycle approach, the parties may need to confirm which specification is current, reconcile any differences and document who is responsible for approving and distributing future revisions.
The assessment may include comparing test parameters, acceptance criteria, analytical methods and stability requirements across each version. It may also require reviewing previously released batches where different standards were applied.
The outcome could include adopting one controlled specification, updating quality agreements, retraining relevant personnel, and establishing a formal change-notification process so that all parties continue working from the same approved requirements.
Raw Material and Supplier Controls May Require Greater Attention
Raw material controls are already an important component of NHP quality. The proposed guide does not create this responsibility for the first time, but it provides more detailed direction on how ingredients should be characterized, assessed, and controlled before they are used in production.
Brands may need stronger access to information regarding ingredient identity, source and origin, supplier specifications, contaminant controls, manufacturing or extraction processes, storage conditions and supplier change notifications.
For brands, the practical change may be greater scrutiny of whether supplier qualification and incoming material controls provide enough information to confirm that each ingredient is suitable for its intended use. This may be particularly important for botanicals, probiotics and other ingredients with greater natural variability.
What Stronger Raw Material and Supplier Controls Could Look Like
A botanical ingredient supplier provides a Certificate of Analysis (COA) showing that the extract meets a marker-compound limit.
Under a less detailed approach, the brand or manufacturer may accept the COA as sufficient evidence that the ingredient meets requirements.
Under the proposed approach, the brand may need to assess whether the documentation also confirms the correct plant species, plant part, extraction ratio, solvent system, source material and applicable contaminant controls.
The outcome may include accepting the material as supported, requesting additional supplier documentation, conducting confirmatory testing, updating the raw material specification, or qualifying an alternative supplier before the ingredient is used in production.
Stability May Become a More Visible Ongoing Requirement
Stability testing is already required to support the assigned shelf life of an NHP. The proposed guide does not create this obligation for the first time, but it places greater emphasis on maintaining stability support throughout the product lifecycle.
Brands may need to reassess whether existing stability data remain representative when the formulation, supplier, packaging, manufacturing site or production process changes, when new commercial batches are introduced, or when stability trends and quality issues emerge.
For brands, this may introduce greater scrutiny of whether there is a documented process for evaluating the impact of change. Not every change will require a new stability study, but the rationale for relying on existing data may need to be scientifically justified and recorded.
What Ongoing Stability Oversight Could Look Like?
A liquid NHP was originally tested in an amber glass bottle but is later marketed in plastic packaging.
Under a less formal approach, the brand may continue relying on the original stability data because the formulation and medicinal ingredients have not changed.
Under the proposed lifecycle approach, the brand may need to assess whether the new packaging changes the product’s exposure to light, oxygen or moisture, or affects preservative effectiveness, container compatibility or product integrity over time.
The assessment could include comparing the barrier properties of the two containers, reviewing compatibility data, evaluating whether the closure system provides equivalent protection and determining whether the original stability batches remain representative of the marketed product.
The outcome may be no further action, targeted packaging compatibility testing, placement of the revised product on stability, a reduced shelf life, or a broader stability study to support the new packaging configuration.
Dosage Form-Specific Quality Expectations Are More Clearly Defined
Quality requirements already apply to all NHP dosage forms. The proposed guide does not create a separate quality obligation for newer or more complex products, but it provides more detailed direction for product formats that may require additional controls.
These include gummies, probiotics, modified-release products, sterile NHPs, oral health products, and products intended for vulnerable populations.
For brands, this may introduce greater scrutiny of whether the specifications, testing and stability program reflect the risks associated with the actual dosage form rather than applying a standard approach used for conventional tablets or capsules.
What More Specific Quality Controls Could Look Like for Gummies
Gummy quality can be affected by moisture, microbial growth, ingredient distribution, texture and physical changes during storage.
Under a less detailed approach, a brand may focus primarily on potency and microbial testing when determining whether the product remains acceptable.
Under the proposed approach, the brand may also need to consider whether attributes such as water activity, dosage-unit uniformity, disintegration, texture and physical integrity remain acceptable through the end of shelf life.
A gummy could continue to meet its potency specification while becoming excessively hard, sticky or unevenly distributed. The assessment may therefore include trending physical changes, reviewing packaging performance and determining whether the existing specifications adequately capture the quality attributes most likely to change over time.
What More Specific Quality Controls Could Look Like for Probiotics
Probiotic products already require appropriate controls for identity, potency and stability. The proposed guide provides more detailed direction on strain-level identity, culture traceability, microbial quality and potency through the end of shelf life.
Under a less detailed approach, a multi-strain probiotic may be assessed primarily using a total colony-forming unit count.
Under the proposed approach, the brand may need to determine whether that total count provides sufficient assurance that each licensed strain remains present and appropriately represented.
The assessment may include reviewing strain identification methods, master and working culture controls, supplier documentation, production records and stability data for each strain. The outcome may include additional strain-specific testing, revised specifications or stronger supplier and manufacturing controls.
Analytical Method and Specification Expectations Are More Clearly Defined
Analytical methods and the FPS are already expected to be scientifically justified. The proposed guide, therefore, does not establish this principle for the first time, but it provides more detailed direction on method suitability, validation, and the development of product-specific specifications.
For brands, the practical change may be greater scrutiny of whether the test method works reliably in the finished product matrix rather than only for the isolated raw material.
What Greater Analytical Method Scrutiny Could Look Like
A recognized method accurately measures a vitamin raw material but produces unreliable results when applied to a finished product containing flavours, colours and botanical extracts.
Under a less detailed approach, the laboratory may continue using the recognized method and rely on the resulting COA.
Under the proposed approach, the brand may need evidence that the method is specific, accurate and suitable for the actual formulation. This may involve assessing whether other ingredients interfere with the analysis, reviewing method-validation or verification data and comparing the method against an alternative analytical approach.
The outcome may include confirming that the method remains suitable, modifying or validating the method for the finished product, revising the specification or reassessing batches tested using the original method. A passing result may not provide meaningful assurance if the method itself has not been shown to perform reliably in the product being tested.
Could the Draft Guide Affect Inspections?
The proposed guide is not a regulation and does not create new legal requirements on its own. Once finalized, however, it may become an important reference point for how Health Canada interprets and assesses existing quality obligations.
Once finalized, it could influence how Health Canada evaluates product quality during:
- Product Licence reviews
- Site Licence assessments
- GMP inspections
- Information requests
- Compliance activities
The expanded level of detail may give inspectors and assessors a clearer benchmark for determining whether a company’s quality controls are adequate.
From a brand perspective, the practical implication is straightforward. Quality decisions may need to be easier to trace, explain, and defend. Informal knowledge, undocumented assumptions or reliance on supplier assurances may be less likely to withstand regulatory scrutiny and jeopardize compliance.
How Should Brands Prepare for the Proposed Quality of Natural Health Products (NHPs) Guide?
Source Nutraceutical, Inc. (SNI) recommends reviewing existing quality systems against current regulatory requirements while also considering the direction outlined in the consultation draft. This can help brands identify where current practices, documentation or supply-chain controls may already require attention, without prematurely implementing provisions that have not yet been finalized.
Particular attention should be given to:
- FPS
- Stability documentation and ongoing monitoring
- Supplier qualification and change-notification procedures
- Manufacturing, laboratory and quality agreements
- Change-control processes
- Access to technical records and analytical methods
- Allocation of responsibilities across the Canadian supply chain
- Technically complex products, including gummies and probiotics
Brands should also monitor the consultation closely, including stakeholder feedback summaries, Health Canada responses and any revisions made before the final guide is published. Consultation drafts are often refined in response to industry feedback, and the final wording may change how specific responsibilities are interpreted, assigned or implemented.
At this stage, the objective should be to strengthen alignment with existing requirements, identify potential gaps and remain prepared to reassess those systems once Health Canada confirms its final expectations.
Which NHP Brands May Be Most Affected by the New Quality of Natural Health Products (NHPs) Guide?
The proposed guide may have the greatest practical impact on companies whose quality systems depend heavily on third parties or older documentation.
This may include:
- Virtual brands that outsource most regulated activities
- Foreign companies entering Canada through a third-party importer
- Companies with large portfolios of older NPNs
- Brands with limited access to manufacturing, testing or stability records
- Gummy and probiotic companies
- Brands relying on limited stability data
- Companies working with several manufacturers, suppliers or laboratories
The common issue is not company size alone. It is whether the Product Licence holder has enough visibility, documentation, and contractual control to demonstrate how product quality is maintained.
Smaller brands may face greater challenges where manufacturers or suppliers retain key technical records, control test methods or provide only limited notice of changes. In those cases, the brand may need to strengthen information-sharing arrangements and clarify access to the records required to support ongoing compliance.
From SNI’s perspective, the brands most exposed are likely to be those that hold the NPN but do not have direct control over the underlying quality information. These companies should pay particular attention to record access, change-notification procedures, quality agreements, and alignment between the Product Licence holder, manufacturer, importer, and laboratory. The earlier these gaps are identified, the easier it will be to respond once Health Canada confirms its final expectations.
Final Remarks
The draft revised Health Canada NHP Quality Guide does not replace the existing regulatory framework, but it does signal a more detailed and lifecycle-oriented interpretation of how quality should be managed. For brands, the immediate priority is to confirm that current systems remain aligned with existing requirements while monitoring how Health Canada refines the draft through consultation feedback and subsequent guidance. The final version may clarify, narrow or reassign certain responsibilities, so companies should avoid overcorrecting too early while still preparing for greater expectations around documentation, oversight, and ongoing quality management.
Preparing for the Revised NHP Quality Guide
With more than 20 years of experience supporting NHP companies, SNI has worked across product licensing, FPS, stability planning, GMP compliance, and post-market regulatory support. Our team has supported more than 1,200 NHP applications, giving us practical insight into how Health Canada evaluates quality information across different products, business models and supply chains.
As the revised NHP Quality Guide develops, SNI can help brands assess existing systems against current requirements, identify areas that may require closer attention under the draft framework and prioritize gaps that could affect licensing, GMP compliance or commercial operations.
Book an introductory call using the following form:
Frequently Asked Questions
Is the Revised Health Canada NHP Quality Guide Currently in Effect?
No. The revised Health Canada NHP Quality Guide is currently a consultation draft. The existing guidance remains in effect until Health Canada publishes a final version. The final guide may also differ from the consultation draft following stakeholder feedback and regulatory review.
Does the Draft Health Canada NHP Quality Guide Create New Regulations?
No. The draft guide does not independently amend the Natural Health Products Regulations. Instead, it provides more detailed guidance on how Health Canada may expect companies to meet existing quality requirements for NHPs. Guidance documents are administrative, not legal, instruments.
Will the Health Canada NHP Quality Guide Require More Product Testing?
Not necessarily. Testing should remain appropriate to the product’s ingredients, dosage form, manufacturing process, and risk profile. However, some brands may identify gaps in their current specifications, analytical methods, stability programs, or supporting quality data when comparing their systems with the draft guide.
Will NHP Brands Need Written Quality Agreements?
The draft Health Canada NHP Quality Guide places greater emphasis on written quality agreements for outsourced activities. Brands should review whether their current manufacturing, laboratory and supply agreements clearly assign quality responsibilities, record ownership, change-notification requirements and issue-escalation procedures.
Could the Revised Health Canada NHP Quality Guide Affect Existing NPNs?
Potentially. Existing NPNs would not automatically become invalid, but Product Licence holders may need to confirm that product specifications, test methods, stability data and supporting quality information remain current and scientifically appropriate.
The content on this website, including information presented in this post, is provided for general informational purposes only and does not constitute legal, regulatory, or professional advice. While efforts are made to ensure accuracy, laws and regulations vary by jurisdiction and may change over time. Readers should not rely on this information as a substitute for advice from qualified legal or regulatory professionals. We disclaim any liability for actions taken based on this content, and users are encouraged to seek guidance specific to their circumstances.
